Autotaxin and lpa receptors represent potential molecular targets for the radiosensitization of murine glioma through effects on tumor vasculature

PLoS ONE

Volumn 6, Issue 7, 2011, Pages

  Schleicher, Stephen M ^a   Thotala, Dinesh K ^d   Linkous, Amanda G ^c   Hu, Rong ^d   Leahy, Kathleen M ^d   Yazlovitskaya, Eugenia M ^b   Hallahan, Dennis E ^d,e,f  

^a VANDERBILT UNIVERSITY   (United States)

^b VANDERBILT INGRAM CANCER CENTER   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e USA   (United States)

^f WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOTAXIN; LYSOPHOSPHATIDIC ACID; LYSOPHOSPHATIDIC ACID RECEPTOR; LYSOPHOSPHATIDIC ACID RECEPTOR 1; LYSOPHOSPHATIDIC ACID RECEPTOR 2; LYSOPHOSPHATIDIC ACID RECEPTOR 3; PROTEIN KINASE B; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; ALKYLGLYCEROPHOSPHOETHANOLAMINE PHOSPHODIESTERASE; BRP LPA; BRP-LPA; LYSOPHOSPHOLIPID; PHOSPHODIESTERASE; RADIOSENSITIZING AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN CELL; CANCER INHIBITION; CANCER RADIOTHERAPY; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; GAMMA IRRADIATION; GENE SILENCING; GLIOMA; GLIOMA CELL; HUMAN; MIGRATION INHIBITION; MOUSE; NONHUMAN; PROTEIN TARGETING; RADIATION RESPONSE; RADIOSENSITIZATION; SIGNAL TRANSDUCTION; TUMOR VASCULARIZATION; UMBILICAL VEIN ENDOTHELIAL CELL; ANIMAL; CELL DEATH; CELL MOTION; CYTOLOGY; DRUG ANTAGONISM; DRUG EFFECT; ENDOTHELIUM CELL; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; RADIATION EXPOSURE; TUMOR CELL LINE; VASCULARIZATION;

MURINAE; MUS;

ANIMALS; CELL DEATH; CELL LINE, TUMOR; CELL MOVEMENT; CELL SURVIVAL; ENDOTHELIAL CELLS; GLIOMA; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; LYSOPHOSPHOLIPIDS; MICE; MOLECULAR TARGETED THERAPY; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHORIC DIESTER HYDROLASES; RADIATION-SENSITIZING AGENTS; RECEPTORS, LYSOPHOSPHATIDIC ACID; SIGNAL TRANSDUCTION;

EID: 79958719984     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0022182     Document Type: Article

References (39)

1. Berens ME, Rutka JT, Rosenblum ML, (1990) Brain tumor epidemiology, growth, and invasion. Neurosurg Clin N Am 1: 1-18.
2. Wen PY, Kesari S, (2004) Malignant gliomas. Curr Neurol Neurosci Rep 4: 218-227.
3. Stracke ML, Krutzsch HC, Unsworth EJ, Arestad A, Cioce V, et al. (1992) Identification, purification, and partial sequence analysis of autotaxin, a novel motility-stimulating protein. J Biol Chem 267: 2524-2529.
4. Stracke ML, Clair T, Liotta LA, (1997) Autotaxin, tumor motility-stimulating exophosphodiesterase. Adv Enzyme Regul 37: 135-144.
5. Stefan C, Gijsbers R, Stalmans W, Bollen M, (1999) Differential regulation of the expression of nucleotide pyrophosphatases/phosphodiesterases in rat liver. Biochim Biophys Acta 1450: 45-52.
6. Gong F, Xiong P, Yang Z, Xu Y, Jiang X, et al. (1999) [An investigation of the polymorphism of HLA class II alleles in the Han population in Hubei Province of China]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 16: 216-219.
7. Stassar MJ, Devitt G, Brosius M, Rinnab L, Prang J, et al. (2001) Identification of human renal cell carcinoma associated genes by suppression subtractive hybridization. Br J Cancer 85: 1372-1382.
8. Kishi Y, Okudaira S, Tanaka M, Hama K, Shida D, et al. (2006) Autotaxin is overexpressed in glioblastoma multiforme and contributes to cell motility of glioblastoma by converting lysophosphatidylcholine to lysophosphatidic acid. J Biol Chem 281: 17492-17500.
9. Umezu-Goto M, Kishi Y, Taira A, Hama K, Dohmae N, et al. (2002) Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. J Cell Biol 158: 227-233.
10. van Meeteren LA, Moolenaar WH, (2007) Regulation and biological activities of the autotaxin-LPA axis. Prog Lipid Res 46: 145-160.
11. Contos JJ, Ishii I, Chun J, (2000) Lysophosphatidic acid receptors. Mol Pharmacol 58: 1188-1196.
12. Hecht JH, Weiner JA, Post SR, Chun J, (1996) Ventricular zone gene-1 (vzg-1) encodes a lysophosphatidic acid receptor expressed in neurogenic regions of the developing cerebral cortex. J Cell Biol 135: 1071-1083.
13. Hoelzinger DB, Nakada M, Demuth T, Rosensteel T, Reavie LB, et al. (2008) Autotaxin: a secreted autocrine/paracrine factor that promotes glioma invasion. J Neurooncol 86: 297-309.
14. Deng W, Shuyu E, Tsukahara R, Valentine WJ, Durgam G, et al. (2007) The lysophosphatidic acid type 2 receptor is required for protection against radiation-induced intestinal injury. Gastroenterology 132: 1834-1851.
15. Xue J, Gan L, Li X, Li J, Qi G, et al. (2010) Effects of lysophosphatidic acid and its receptors LPA(1/3) on radiation pneumonitis. Oncology reports 24: 1515-1520.
16. Yu S, Murph MM, Lu Y, Liu S, Hall HS, et al. (2008) Lysophosphatidic acid receptors determine tumorigenicity and aggressiveness of ovarian cancer cells. J Natl Cancer Inst 100: 1630-1642.
17. Vivanco I, Sawyers CL, (2002) The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2: 489-501.
18. LoPiccolo J, Granville CA, Gills JJ, Dennis PA, (2007) Targeting Akt in cancer therapy. Anticancer Drugs 18: 861-874.
19. Kandel ES, Hay N, (1999) The regulation and activities of the multifunctional serine/threonine kinase Akt/PKB. Exp Cell Res 253: 210-229.
20. Roy HK, Olusola BF, Clemens DL, Karolski WJ, Ratashak A, et al. (2002) AKT proto-oncogene overexpression is an early event during sporadic colon carcinogenesis. Carcinogenesis 23: 201-205.
21. Tanno S, Yanagawa N, Habiro A, Koizumi K, Nakano Y, et al. (2004) Serine/threonine kinase AKT is frequently activated in human bile duct cancer and is associated with increased radioresistance. Cancer Res 64: 3486-3490.
22. Chakravarti A, Zhai G, Suzuki Y, Sarkesh S, Black PM, et al. (2004) The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas. J Clin Oncol 22: 1926-1933.
23. Wachsberger P, Burd R, Dicker AP, (2003) Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: exploring mechanisms of interaction. Clin Cancer Res 9: 1957-1971.
24. Yazlovitskaya EM, Linkous AG, Thotala DK, Cuneo KC, Hallahan DE, (2008) Cytosolic phospholipase A2 regulates viability of irradiated vascular endothelium. Cell Death Differ 15: 1641-1653.
25. Linkous A, Geng L, Lyshchik A, Hallahan DE, Yazlovitskaya EM, (2009) Cytosolic phospholipase A2: targeting cancer through the tumor vasculature. Clin Cancer Res 15: 1635-1644.
26. Jiang G, Xu Y, Fujiwara Y, Tsukahara T, Tsukahara R, et al. (2007) Alpha-substituted phosphonate analogues of lysophosphatidic acid (LPA) selectively inhibit production and action of LPA. ChemMedChem 2: 679-690.
27. Prestwich GD, Gajewiak J, Zhang H, Xu X, Yang G, et al. (2008) Phosphatase-resistant analogues of lysophosphatidic acid: agonists promote healing, antagonists and autotaxin inhibitors treat cancer. Biochim Biophys Acta 1781: 588-594.
28. Hoelzinger DB, Demuth T, Berens ME, (2007) Autocrine factors that sustain glioma invasion and paracrine biology in the brain microenvironment. J Natl Cancer Inst 99: 1583-1593.
29. Nam SW, Clair T, Kim YS, McMarlin A, Schiffmann E, et al. (2001) Autotaxin (NPP-2), a metastasis-enhancing motogen, is an angiogenic factor. Cancer Res 61: 6938-6944.
30. Griffioen AW, Molema G, (2000) Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacol Rev 52: 237-268.
31. Baker DL, Desiderio DM, Miller DD, Tolley B, Tigyi GJ, (2001) Direct quantitative analysis of lysophosphatidic acid molecular species by stable isotope dilution electrospray ionization liquid chromatography-mass spectrometry. Analytical biochemistry 292: 287-295.
32. Cechin SR, Dunkley PR, Rodnight R, (2005) Signal transduction mechanisms involved in the proliferation of C6 glioma cells induced by lysophosphatidic acid. Neurochem Res 30: 603-611.
33. Chautard E, Loubeau G, Tchirkov A, Chassagne J, Vermot-Desroches C, et al. (2010) Akt signaling pathway: a target for radiosensitizing human malignant glioma. Neuro Oncol 12: 434-443.
34. Fidler IJ, (1990) Critical factors in the biology of human cancer metastasis: twenty-eighth G.H.A. Clowes memorial award lecture. Cancer Res 50: 6130-6138.
35. Liotta LA, Steeg PS, Stetler-Stevenson WG, (1991) Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 64: 327-336.
36. Ptaszynska MM, Pendrak ML, Stracke ML, Roberts DD, (2010) Autotaxin signaling via lysophosphatidic acid receptors contributes to vascular endothelial growth factor-induced endothelial cell migration. Mol Cancer Res 8: 309-321.
37. Manning TJ Jr, Parker JC, Sontheimer H, (2000) Role of lysophosphatidic acid and rho in glioma cell motility. Cell Motil Cytoskeleton 45: 185-199.
38. Xia HH, Yang Y, Chu KM, Gu Q, Zhang YY, et al. (2009) Serum macrophage migration-inhibitory factor as a diagnostic and prognostic biomarker for gastric cancer. Cancer 115: 5441-5449.
39. Croset M, Brossard N, Polette A, Lagarde M, (2000) Characterization of plasma unsaturated lysophosphatidylcholines in human and rat. The Biochemical journal 345 (Pt 1:): 61-67.